Business Context and Reporting Period
Company: Alpha Tau Medical Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of April 2026
Date of Filing: April 27, 2026
The filing serves to distribute a press release announcing the presentation of pancreatic cancer data at the upcoming ASCO Annual Meeting. The data combines results from three Alpha DaRT® pancreatic cancer studies.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a corporate event and does not contain financial statements or quantitative financial data.
Material Changes
No material financial changes versus a prior comparable period are reported in this filing. The primary update is the strategic milestone of presenting clinical data from three studies.
Guidance, Outlook, and Risks
Management Commentary: The Company is highlighting its Alpha DaRT® technology platform through the presentation of combined results from three pancreatic cancer studies at the ASCO Annual Meeting.
Risks and Contingencies: The filing includes standard legal disclaimers stating that the information furnished is not "filed" under Section 18 of the Exchange Act and is not subject to the liabilities of that section. No specific new risks or contingencies are detailed in the text provided.
Investor Verification Checklist
- Verify the specific clinical outcomes and statistical significance of the three Alpha DaRT® pancreatic cancer studies presented at ASCO.
- Confirm the timeline for regulatory submissions or commercialization based on the presented data.
- Review the full text of the attached press release (Exhibit 99.1) for detailed study endpoints not summarized in the Form 6-K.